[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wuhan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":209},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,65,92,115,142,165,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100557044","predictive-algorithms-for-critical-rehabilitation-outcomes-100557044",false,"NCT06532994","Predictive Algorithms for Critical Rehabilitation Outcomes","Development and Validation of a Prediction Algorithms to Estimate the Clinical Effect of Early Rehabilitation on ICU Survivors Received Mechanical Ventilation in the ICU","Inclusion Criteria:\n\n1. Age older than 18 years;\n2. Received mechanical ventilation, including endotracheal intubation and tracheostomy, during ICU admission;\n3. Met the rehabilitation intervention indications outlined in the \"Chinese Expert Consensus on Neurocritical Rehabilitation\" during ICU admission and underwent corresponding early rehabilitation interventions, including but not limited to arousal therapy for consciousness disorders, early active\u002Fpassive mobilization, comprehensive pulmonary rehabilitation, etc.;\n4. No mortality events occurred during ICU admission;\n5. Informed consent form signed by family members or the patient.\n\nExclusion Criteria:\n\n1. Pediatric patients under 18 years of age;\n2. Hospitalized patients in the ICU who did not receive mechanical ventilation;\n3. Patients in the ICU who did not undergo early rehabilitation interventions;\n4. mortality events occurred during ICU admission;\n5. Patients transferred out of the ICU due to treatment abandonment by family members;\n6. Family refusal to sign the informed consent form or patient refusal to sign the informed consent form when conscious and competent.","ALL","18 Years","90 Years",{"count":20,"type":21},250,"ESTIMATED","OBSERVATIONAL","An increasing amount of evidence from evidence-based medicine indicates that early rehabilitation intervention for patients receiving mechanical ventilation is safe and feasible, and can promote functional recovery and reduce hospital stay. However, the conscious state, respiratory function, and daily living activities of these patients after being discharged from the ICU vary greatly, and some patients do not show obvious benefits. How to identify which patients may have benefit from early rehabilitation is a key issue that needs to be addressed in critical care rehabilitation. This study aims to investigate the clinical data related to the disease of the ICU survivors who received mechanical ventilation as the research object, by collecting their clinical data when receiving early rehabilitation intervention, and constructing a clinical prediction model for the efficacy of early rehabilitation intervention in the ICU through the selection of optimal regression equation or machine learning algorithm. The application of this model can effectively determine whether ICU inpatients need early rehabilitation intervention, thereby reducing complication rates and improving their quality of life.",[25,26,27,28],"Intensive Care","Mechanical Ventilation","Rehabilitation","Algorithms","RECRUITING","2026-04-15",{"date":32,"type":33},"2026-04-21","ACTUAL",{"date":35,"type":33},"2024-08-01",{"date":37,"type":21},"2026-12-30",{"name":39,"class":40},"Wuhan University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100554271","a-real-world-research-on-the-prevention-and-treatment-of-peritoneal-metastasis-and-malignant-ascites-by-intraperitoneal-infusion-of-rmhtnf-in-gastric-and-colorectal-malignant-tumors-100554271","NCT06496919","A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors","A Multicenter Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors","Inclusion Criteria:\n\n* 1\\. The initial pathological diagnosis is gastric adenocarcinoma and colorectal adenocarcinoma, with clinical stage progression or advanced stage (cII-IV stage).\n\n  2\\. Patients with recurrent\u002Fmetastatic gastric adenocarcinoma and colorectal cancer.\n\n  3\\. Age range from 18 to 80 years old; 4. Male or non pregnant or lactating female; 5. The bone marrow reserve function is good, and the blood routine meets the following conditions: white blood cell count ≥ 3.5 × 109\u002FL, neutrophils ≥ 1.5 × 109\u002FL, platelet count ≥ 100 × 109\u002FL, hemoglobin ≥ 90 g\u002FL; 6. The organ function is good, and the biochemical examination meets the following conditions: ALT ≤ 2.5 x Upper Limit of Normal (ULN), AST ≤ 2.5 x ULN, serum total bilirubin ≤ 1.5 x ULN, and blood creatinine ≤ 1.5 x ULN; 7. Functional status: 0-1 (ECOG); 8. preoperative ASA grading I-III; 9. Informed consent form has been signed for clinical treatment.\n\nExclusion Criteria:\n\n* 1\\. Individuals who are allergic to TNF, biological products, or penicillin; 2. Those who do not meet the inclusion criteria during pregnancy or lactation; 3. Other situations where the researcher believes that patients are not suitable to participate in this trial.","80 Years",{"count":51,"type":21},300,"Peritoneal metastasis is the main factor leading to poor prognosis in patients with gastric cancer or colorectal cancer. Although current systemic treatment regimens can prolong the time to peritoneal metastasis, the long-term survival rate is still poor. This is mainly due to the presence of the peritoneal plasma barrier, which limits the penetration of anti-tumor drugs and thus restricts the efficacy. In contrast, the use of intraperitoneal infusion chemotherapy allows anti-tumor drugs to directly reach the abdominal cavity, exposing metastatic nodules to high concentrations of drugs, and has a significant therapeutic effect on peritoneal metastases, resulting in better therapeutic effects Tumor necrosis factor (TNF) is a small molecule protein secreted by macrophages. There are two types of TNF - α: α and ß. TNF - α is produced by activated monocytes and macrophages, also known as cachectin. TNF - α is produced by activated lymphocytes, also known as lymphotoxins, and the two have similar activity. Previous studies have shown that rmhTNF is safe for intraoperative perfusion in gastrointestinal tumors.\n\nIn this real-world study, we will observe the safety and effectiveness of rmhTNF intraperitoneal perfusion in actual clinical settings.",[54],"Gastric Cancer",[56],"rmhTNF, gastric cancer, colorectal cancer, peritoneal metastasis, intraperitoneal infusion chemotherapy","NOT_YET_RECRUITING","2024-07-03",{"date":60,"type":33},"2024-07-11",{"date":35,"type":21},{"date":63,"type":21},"2027-07-31",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100552214","a-real-world-study-of-neoadjuvantconversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents-100552214","NCT06470178","A Real-World Study of Neoadjuvant\u002FConversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents","A Real-World Study of Neoadjuvant\u002FConversion Therapy for Locally Advanced or Metastatic Colorectal Cancer With Chemotherapy Combined With Anti-Angiogenic Targeted Agents","Inclusion Criteria:\n\n* Patients must meet all of the following criteria to be enrolled in this study:\n\n  1. Age ≥18 years and ≤75 years;\n  2. Either gender;\n  3. Patients with histologically confirmed colorectal cancer. For the neoadjuvant treatment cohort: Rectal cancer is limited to high rectal cancer, but patients with mid to low rectal cancer who are unwilling or unsuitable for neoadjuvant chemoradiotherapy can also be included.\n  4. Neoadjuvant treatment cohort: Clinically staged as stage II (T3-4N0M0) or stage III (T1-4N1-2M0) and initially resectable; patients with clinical stage M1 but initially resectable can also be included in the neoadjuvant treatment cohort, such as patients with stage IV liver oligometastasis. Conversion treatment cohort: Patients with initially unresectable but potentially resectable locally advanced or advanced distant metastatic colorectal cancer (according to AJCC 8th), and patients with locally advanced low rectal cancer who are unsuitable or unwilling to undergo chemoradiotherapy can also be included.\n  5. Have received chemotherapy and fruquintinib for at least 2 cycles. For the neoadjuvant therapy cohort, patients who have not previously received anticancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy, etc.). The patients are eligible for inclusion in the analysis set if they have received fruquintinib treatment for at least 2 cycles and have undergone at least one tumor assessment after baseline. All patients included in the efficacy analysis are included in the safety analysis set.\n  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 before treatment.\n  7. Expected survival time of \\>6 months before neoadjuvant therapy and \\>3 months before conversion therapy.\n  8. No significant organ dysfunction or drug contraindications before receiving neoadjuvant or conversion therapy.\n  9. There is no mandatory requirement for target lesions. Objective response rate (ORR) assessment is based on all evaluable patients, regardless of the presence of target lesions. For patients without target lesions, those assessed as non PR\u002Fnon PD will be analyzed as stable disease (SD).\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria are not eligible to enter the study:\n\n  1. History of other primary malignant tumors, except: (1) complete remission of malignant tumors at least 2 years before enrollment and no need for other treatment during the study period; (2) adequately treated non-melanoma skin cancer or malignant melanoma without evidence of disease recurrence; (3) adequately treated in situ carcinoma.\n  2. dMMR\u002FMSI-H.\n  3. Female patients who are pregnant or lactating.\n  4. Known allergy (Grade 3 or higher allergic reaction) or contraindication to anti-angiogenic drugs or chemotherapy drug components.\n  5. Use of non-study drug treatments during the study period that may interfere with the analysis.\n  6. Patients who did not undergo any tumor efficacy assessment after receiving neoadjuvant or conversion therapy.\n  7. Less than 2 cycles of fruquintinib neoadjuvant or conversion therapy.\n  8. Patients with insufficient follow-up information as judged by the investigator (such as not returning to the hospital for treatment or efficacy assessment after initial treatment).","75 Years",{"count":74,"type":21},70,"Fruquintinib is already the standard third-line treatment for metastatic colorectal cancer, but the efficacy of fruquintinib in neoadjuvant and conversion therapy for locally advanced\u002Fadvanced colorectal cancer has not yet been reported. This study aims to observe the efficacy and safety of fruquintinib combined with chemotherapy in neoadjuvant or conversion therapy for colorectal cancer patients in the real world.",[77],"Colorectal Cancer",[79,80,81,82,83],"Fruquintinib","anti-angiogenic targeted therapies","colorectal cancer","neoadjuvant therapy","conversion therapy","2024-06-17",{"date":86,"type":33},"2024-06-24",{"date":88,"type":21},"2025-05-01",{"date":90,"type":21},"2027-04-30",{"name":39,"class":40},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":41},"100551785","a-real-world-study-of-neoadjuvantconversion-therapy-for-locally-advanced-or-metastatic-gastric-cancer-100551785","NCT06464601","A Real-World Study of Neoadjuvant\u002FConversion Therapy for Locally Advanced or Metastatic Gastric Cancer","A Real-World Study of Neoadjuvant\u002FConversion Therapy for Locally Advanced or Metastatic Gastric Cancer With Chemotherapy Combined With Immune Checkpoint Inhibitors and Anti-Angiogenic Targeted Agents","Inclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled in this study:\n\n1. Age ≥18 years and ≤75 years;\n2. Either gender;\n3. Histologically confirmed gastric or gastroesophageal junction adenocarcinoma. For neoadjuvant therapy cohort: candidates for Initial potentially curative surgery with cII, cIII, or cIVA stage disease (\\>cT2N0-3M0 or cT0-4N+M0); no distant metastasis. For conversion therapy cohort: patients with locally advanced unresectable or stage IV metastatic disease (per AJCC 8th edition). Pre-treatment imaging (CT or MRI, PET-CT, etc.) must indicate only one of the following unresectable factors:\n\n(1) Lymph node metastasis around the abdominal aorta (2) Virchow lymph node metastasis (left supraclavicular lymph node metastasis) (3) Resectable liver metastases: 2 to 5 metastatic lesions, total diameter \\>5 cm and ≤8 cm, tumor invades the vena cava or portal vein (4) Lung metastases (5) Isolated peritoneal implantation\n\n4\\. Have received chemotherapy, immune checkpoint inhibitors, and fruquintinib for at least 2 cycles. For the neoadjuvant therapy cohort, patients who have not previously received anticancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy, etc.). The patients are eligible for inclusion in the analysis set if they have received fruquintinib treatment for at least 2 cycles and have undergone at least one baseline tumor assessment. All patients included in the efficacy analysis are included in the safety analysis set.\n\n5\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 before treatment.\n\n6\\. Expected survival time of \\>6 months before neoadjuvant therapy and \\>3 months before conversion therapy.\n\n7\\. No significant organ dysfunction or drug contraindications before receiving neoadjuvant or conversion therapy.\n\n8\\. There is no mandatory requirement for target lesions. Objective response rate (ORR) assessment is based on all evaluable patients, regardless of the presence of target lesions. For patients without target lesions, those assessed as non PR\u002Fnon PD will be analyzed as stable disease (SD).\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria are not eligible to enter the study:\n\n1. History of other primary malignant tumors, except: (1) complete remission of malignant tumors at least 2 years before enrollment and no need for other treatment during the study period; (2) adequately treated non-melanoma skin cancer or malignant melanoma without evidence of disease recurrence; (3) adequately treated in situ carcinoma.\n2. Conversion therapy cohort: Diagnosis of HER2-positive gastric or gastroesophageal junction adenocarcinoma.\n3. Conversion therapy cohort: Evidence of distant metastases beyond oligometastases as defined in the inclusion criteria before the first dose of study treatment (such as brain, bone, etc.).\n4. Female patients who are pregnant or lactating.\n5. Known allergy (Grade 3 or higher allergic reaction) or contraindication to anti-angiogenic drugs, any monoclonal antibody, or chemotherapy drug components.\n6. Use of non-study drug treatments during the study period that may interfere with the analysis.\n7. Patients who did not undergo any tumor efficacy assessment after receiving neoadjuvant or conversion therapy.\n8. Less than 2 cycles of fruquintinib neoadjuvant or conversion therapy.\n9. Patients with insufficient follow-up information as judged by the investigator (such as not returning to the hospital for treatment or efficacy assessment after initial treatment).",{"count":74,"type":21},"Chemotherapy, immune checkpoint inhibitors, and anti-angiogenic targeted therapies have been explored in combination for neoadjuvant and conversion therapies. However, the efficacy of the novel anti-angiogenic agent fruquintinib in combination with immune checkpoint inhibitors and chemotherapy in the neoadjuvant and conversion treatment of locally advanced or metastatic gastric cancer has not been reported. This study aims to observe the efficacy and safety of fruquintinib combined with immune checkpoint inhibitors and chemotherapy in real-world settings.",[54],[103,80,104,105,106],"fruquintinib","neoadjuvant treatment","conversion treatment","gastric cancer","2024-06-10",{"date":109,"type":33},"2024-06-18",{"date":111,"type":21},"2025-04-01",{"date":113,"type":21},"2027-03-31",{"name":39,"class":40},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":122,"minAge":17,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100433855","phase-4-exploratory-study-of-neoadjuvant-treatment-of-her2-positive-breast-cancer-with-py-in-combination-with-hp-100433855","NCT04929548","Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP","Exploratory Study of Triple-targeted Neoadjuvant Treatment of HER2-positive Breast Cancer With Pyrotinib in Combination With Trastuzumab and Pertuzumab","Inclusion Criteria:\n\n* Female patients aged 18-70 years.\n* ECOG score must be 0 or 1.\n* Patients with clinical stage II to III new breast cancer, all diagnosed by hollow-core needle aspiration biopsy pathological histology prior to treatment and surgically resectable breast cancer with positive immunohistochemical staining (IHC) for HER2 (3+) or HER2 (2+) supplemented with fluorescence in situ hybridization technique (FISH).\n* The presence of at least one measurable lesion according to RECIST 1.1 criteria.\n* Exclusion of distant metastases by abdominal B-ultrasound, chest X-ray and whole-body bone scan prior to neoadjuvant chemotherapy, and for lymph nodes in the enlarged area fine needle aspiration cytology is required to clarify the presence of tumor metastases without a history of remaining malignancies.\n* Expected survival of not less than 12 weeks.\n* No previous treatment, including chemotherapy, radiotherapy, targeted therapy, and biologic therapy. -Exclusion Criteria\n\nExclusion Criteria:\n\n* Female patients of childbearing age who are pregnant, breastfeeding, or unwilling to use effective contraception throughout the trial period.\n* Patients with combined severe cardiac, hepatic, renal, or endocrine system diseases and with expected survival of \\\u003C 2 years for the above diseases.\n* Inability to swallow, intestinal obstruction, the presence of other factors affecting drug administration and absorption or a history of allergy to this drug\n* Karnofsky scale score below 60\n* Patients with metastatic breast cancer or bilateral breast cancer.\n* Patients with inflammatory breast cancer.\n* Those with a left ventricular ejection fraction (LVEF) \\\u003C55% on echocardiography\n* Those who are deemed by the personnel to be otherwise unsuitable for clinical trials.","FEMALE","70 Years",{"count":125,"type":21},20,"INTERVENTIONAL",[128],"PHASE4","This study is a single-arm, single-center exploratory clinical study. Twenty patients with early-stage HER2-positive breast cancer are planned to be included, and the primary objective is to evaluate the efficacy of neoadjuvant regimen of Pyrotinib in combination with trastuzumab + pertuzumab.",[131],"Breast Cancer",[131,133,134],"Neoadjuvant","Targeted Therapy","2022-01-04",{"date":137,"type":33},"2022-01-05",{"date":137,"type":21},{"date":140,"type":21},"2027-09-20",{"name":39,"class":40},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":149,"targetDuration":4,"studyType":126,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":41},"100413631","function-integrity-of-neck-anatomy-in-thyroid-surgery-100413631","NCT04666103","Function Integrity of Neck Anatomy in Thyroid Surgery","Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients diagnosed with unilateral thyroid carcinoma and contralateral benign nodule confirmed by preoperative ultrasound-guided fine-needle aspiration cytology;\n* Patients with contralateral nodules ≤ 20mm and located in the thyroid gland;\n* Patients with clinical node-negative cervical compartment at palpation and neck ultrasound.\n\nExclusion Criteria:\n\n* Previous history of neck surgery\n* Previous history of neck radiation therapy",{"count":150,"type":21},1264,[152],"NA","Recent trends in the management of patients with low-risk papillary thyroid carcinoma who have a nonsuspicious or cytologically benign contralateral nodule call into question the need for routine total thyroidectomy. Although the lobectomy for the unilateral thyroid cancer with contralateral benign nodules is sufficient treatment, some of the patients might suffer from the anxiety of the residual benign thyroid nodule and tend to choose total thyroidectomy, which might be overtreatment.\n\nThermal ablation has been proven to be effective in achieving nodule shrinkage and being also free from major complications. In our institution, intraoperative RFA was a proposed alternative strategy to treat the contralateral benign nodules after the thyroid lobectomy for the malignant lobe, which was found to have a better quality of life on anxiety, physiological health, social family, psychological and sensory mentions with a considerable complication rate.",[155,156,157],"Thyroid Carcinoma","Thyroid Nodule (Benign)","Ablation; Retina","2020-12-11",{"date":160,"type":33},"2020-12-14",{"date":158,"type":33},{"date":163,"type":21},"2026-12-12",{"name":39,"class":40},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":122,"minAge":17,"maxAge":49,"enrollmentInfo":172,"targetDuration":4,"studyType":126,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":183,"leadSponsor":185,"locationsCount":41},"100413614","nomogram-to-predict-breast-cancer-related-lymphedema-100413614","NCT04665882","Nomogram to Predict Breast Cancer Related Lymphedema","Intraoperative Nomogram to Predict Breast Cancer- Related Lymphedema Based in Artificial Intelligence Image Recognition: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18 years or older with T1-3 invasive breast cancer;\n* Clinically node-positive breast cancer, defined as positive on preoperative axillary palpation, ultrasound examination, and computed tomography scan with contrast;\n* Patients who underwent mastectomy with a positive sentinel lymph node (SLN);\n* Patients who underwent breast-conserving surgery containing more than two positive SLNs.\n\nExclusion Criteria:\n\n* Neoadjuvant chemotherapy;\n* Previous history of breast cancer.",{"count":173,"type":21},600,[152],"It has been hypothesized that damaged arm lymphatic drainage is associated with the arm lymphedema after axillary lymph node dissection (ALND). However, the majority of breast cancer patients with complete ALND has not suffered from arm lymphedema, which appears to be due to the residual arm lymph nodes that has not been removed in the axillary dissection. With the compensation of the residual arm lymph flow above the level of axillary vein, the arm lymphatic drainage could keep balance and remain normal function.\n\nThis arm lymphedema prediction model that included the protective factor, the proportion of arm lymph flow above the level of axillary vein, allows intraoperative intervention to be performed for the high-risk group. The arm lymphatics of these distinguished patients would be preserved to eliminate the occurrence of arm lymphedema in this study.",[131,177,178,179],"Axillary Lymph Node Dissection","Breast Cancer Related Lymphedema","Axillary Reverse Mapping",{"date":181,"type":33},"2020-12-16",{"date":158,"type":33},{"date":184,"type":21},"2027-12-31",{"name":39,"class":40},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":122,"minAge":17,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":126,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":41},"100411452","surgical-intervention-for-refractory-granulomatous-lobular-mastitis-100411452","NCT04637711","Surgical Intervention for Refractory Granulomatous Lobular Mastitis","Randomized Controlled Trial for 'Focus Clearing + Whole Breast Exploration and Washing + One-Stage Micro Plastic Surgery' Treatment for Granulomatous Lobular Mastitis","Inclusion Criteria:\n\n* Patients aged 18 years or older with granulomatous lobular mastitis\n* Patients without surgical treatment;\n* Extensive lesions involving two or more quadrants of the breast, or accompanied by abscess, sinus fistula formation, skin rupture and other complex lesions;\n* Patients volunteered to participate in the study after informed consent.\n\nExclusion Criteria:\n\n* Patients were diagnosed with mastitis with other definite etiology confirmed by pathology\n* Patients who chose conservative treatment and did not receive surgical treatment\n* Combined with other basic diseases, unable to tolerate surgery\n* Patients in pregnancy.","60 Years",{"count":51,"type":21},[152],"Granulomatous lobular mastitis (GLM) belongs to a group of benign diseases, which is mainly treated with glucocorticoids and surgical treatment. Nowadays, in China, surgical treatment has gradually become the mainstream, but the timing and the extent of surgery are still controversial, and different literatures report that the recurrence rate after surgery is 20-50%. Empirical lesion resection is generally used. We believe that the main reason for the high recurrence rate is the incomplete removal of the breast lesions. Because GLM is often characterized with microabscesses formation, empirical resection is likely to have residual lesions that are not visible to the naked eye. In order to reduce the postoperative recurrence rate and protect the breast appearance as much as possible, we propose a surgical plan : granulomatous lobular mastitis \"lesion removal + whole breast exploration and flushing + one-stage microplastic surgery\". The purpose of this study was to compare this surgical scheme of granulomatous lobular mastitis with existing surgical schemes, and to compare the overall benefits of the two for patients with GLM. We aim to protect the breast appearance on the premise of low recurrence, improve the quality of life of GLM patients, and standardize GLM surgical schemes.",[198],"Refractory Granulomatous Lobular Mastitis",[200],"granulomatous lobular mastitis ；refractory；surgery","2020-11-16",{"date":203,"type":33},"2020-11-20",{"date":205,"type":33},"2020-11-01",{"date":207,"type":21},"2027-06-30",{"name":39,"class":40},""]